Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas April 21, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC who Experienced Disease Progression on or After Platinum-Based Chemotherapy April 21, 2026
ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
Swiss medical authority approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) combination as 1L maintenance therapy for ES-SCLC December 2, 2025
First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC November 18, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
WCLC 2025: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with ES SCLC in IDeate-Lung01 Ph 2 Trial September 9, 2025
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage SCLC August 19, 2025
First Patient Dosed in Ph 3 Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy August 12, 2025
